Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dry eye
Biotech
Alcon’s $770M Aerie takeover delivers phase 3 dry eye wins
The lead candidate in the acquired pipeline met the primary phase 3 endpoint, positioning Alcon to file for FDA approval in the middle of the year.
Nick Paul Taylor
Jan 10, 2024 5:40am
Protein seen in dry eye disease injury may help eyes heal
Jan 3, 2023 10:49am
After late-study switch, Aldeyra hails win in dry eye phase 3
Jun 8, 2022 9:30am
